Clinical Trial Update: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lixisenatide on postprandial lipid response in obese patients with Type 2 Diabetes Mellitus; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Lixisenatide (lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type II Diabetes Mellitus | Phase 2 | Status: TERMINATED